Intech Investment Management LLC Purchases 24,582 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Intech Investment Management LLC increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 370.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,221 shares of the specialty pharmaceutical company’s stock after buying an additional 24,582 shares during the period. Intech Investment Management LLC owned 0.05% of Jazz Pharmaceuticals worth $3,845,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth about $25,000. Jones Financial Companies Lllp lifted its position in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 130 shares in the last quarter. UMB Bank n.a. lifted its position in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares in the last quarter. Lindbrook Capital LLC lifted its position in Jazz Pharmaceuticals by 82.6% during the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 176 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its position in Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after buying an additional 172 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares of the company’s stock, valued at approximately $966,323.72. This represents a 13.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Robert Iannone sold 2,403 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $138.41, for a total value of $332,599.23. Following the sale, the chief marketing officer now directly owns 79,621 shares of the company’s stock, valued at approximately $11,020,342.61. The trade was a 2.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $142.07 on Thursday. The stock has a 50-day moving average of $130.66 and a 200-day moving average of $121.32. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $8.63 billion, a PE ratio of 20.01, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on JAZZ. Morgan Stanley reiterated an “overweight” rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Barclays restated an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Piper Sandler restated an “overweight” rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Royal Bank of Canada cut their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.